ArticleTranslational lung cancer research2023

Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study.

Lian Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.